See more : urban-gro, Inc. (UGRO) Income Statement Analysis – Financial Results
Complete financial analysis of Accolade, Inc. (ACCD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Accolade, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- HIGH ARCTIC OVERSEAS HOLDINGS C (HOH.V) Income Statement Analysis – Financial Results
- Canadian Oil Recovery & Remediation Enterprises Ltd. (CRVYF) Income Statement Analysis – Financial Results
- B&M European Value Retail S.A. (BME.L) Income Statement Analysis – Financial Results
- PT Wahana Pronatural Tbk (WAPO.JK) Income Statement Analysis – Financial Results
- Shandong Polymer Biochemicals Co., Ltd. (002476.SZ) Income Statement Analysis – Financial Results
Accolade, Inc. (ACCD)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.accolade.com
About Accolade, Inc.
Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|---|
Revenue | 414.29M | 363.14M | 310.02M | 170.36M | 132.51M | 94.81M | 76.83M |
Cost of Revenue | 222.23M | 198.91M | 169.02M | 93.67M | 73.69M | 60.57M | 53.44M |
Gross Profit | 192.06M | 164.24M | 141.00M | 76.69M | 58.82M | 34.24M | 23.39M |
Gross Profit Ratio | 46.36% | 45.23% | 45.48% | 45.01% | 44.39% | 36.12% | 30.45% |
Research & Development | 99.16M | 101.35M | 83.66M | 49.96M | 42.31M | 35.71M | 31.49M |
General & Administrative | 62.12M | 81.21M | 99.11M | 31.58M | 26.15M | 19.67M | 21.12M |
Selling & Marketing | 100.07M | 99.11M | 86.77M | 33.71M | 30.05M | 23.46M | 22.26M |
SG&A | 162.19M | 180.32M | 185.87M | 65.30M | 56.20M | 43.12M | 43.39M |
Other Expenses | 45.16M | 46.38M | 42.61M | 8.21M | 8.52M | -90.00K | -26.00K |
Operating Expenses | 307.20M | 328.05M | 312.14M | 123.46M | 107.03M | 88.22M | 82.85M |
Cost & Expenses | 528.75M | 526.95M | 481.16M | 217.14M | 180.71M | 148.79M | 136.29M |
Interest Income | 0.00 | 255.00K | 2.91M | 3.72M | 2.93M | 2.37M | 0.00 |
Interest Expense | 0.00 | 255.00K | 2.91M | 3.72M | 2.93M | 2.37M | 1.80M |
Depreciation & Amortization | 45.16M | 47.38M | 42.61M | 8.21M | 8.52M | 9.39M | 7.98M |
EBITDA | -71.19M | -110.35M | -130.92M | -38.71M | -39.80M | -44.68M | -51.51M |
EBITDA Ratio | -17.18% | 50.19% | -41.50% | -22.72% | -30.03% | -47.12% | -67.04% |
Operating Income | -114.45M | 135.90M | -171.14M | -46.78M | -48.20M | -53.98M | -59.46M |
Operating Income Ratio | -27.63% | 37.42% | -55.20% | -27.46% | -36.38% | -56.93% | -77.39% |
Total Other Income/Expenses | 15.88M | 240.00K | -3.04M | -3.87M | -3.03M | -2.46M | -1.83M |
Income Before Tax | -98.57M | -463.27M | -128.76M | -50.65M | -51.24M | -56.44M | -61.29M |
Income Before Tax Ratio | -23.79% | -127.57% | -41.53% | -29.73% | -38.67% | -59.53% | -79.77% |
Income Tax Expense | 1.24M | -3.62M | -5.64M | 4.00K | 129.00K | 55.00K | 1.77M |
Net Income | -99.81M | -459.65M | -123.12M | -50.65M | -51.37M | -56.50M | -61.29M |
Net Income Ratio | -24.09% | -126.58% | -39.71% | -29.73% | -38.76% | -59.59% | -79.77% |
EPS | -1.33 | -6.45 | -1.93 | -1.72 | -1.05 | -1.63 | -1.77 |
EPS Diluted | -1.33 | -6.45 | -1.93 | -1.72 | -1.05 | -1.63 | -1.77 |
Weighted Avg Shares Out | 74.91M | 71.28M | 63.82M | 29.37M | 48.79M | 34.63M | 34.63M |
Weighted Avg Shares Out (Dil) | 74.91M | 71.28M | 63.82M | 29.37M | 48.79M | 34.63M | 34.63M |
ACCD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Accolade, Inc. and Encourages Shareholders to Contact the Firm!
Accolade, Inc. (ACCD) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
Investors Of ACCD Are Urged By The Schall Law Firm To Participate In The Investigation Of Securities Fraud At Accolade, Inc
After Plunging -47.01% in 4 Weeks, Here's Why the Trend Might Reverse for Accolade (ACCD)
Accolade, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ACCD
ACCD STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Accolade, Inc. and Encourages Investors to Contact the Firm!
Accolade, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - ACCD
Shareholder Rights Advocates at Levi & Korsinsky Investigate Accolade, Inc. (ACCD) Regarding Possible Securities Fraud Violations
ACCD Investors Are Encouraged By The Schall Law Firm To Join The Securities Fraud Probe Into Accolade, Inc
Levi & Korsinsky Reminds Accolade Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ACCD
Source: https://incomestatements.info
Category: Stock Reports